Jaypirca (pirtobrutinib) — Medica
Waldenström macroglobulinemia/lymphoplasmacytic lymphoma
Initial criteria
- Patient is age ≥ 18 years
- Patient has tried at least one systemic regimen (e.g., Brukinsa, Imbruvica, rituximab, bendamustine, cyclophosphamide, dexamethasone, bortezomib, Kyprolis, or Ninlaro)
Approval duration
1 year